Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) ...

H.C. Wainwright maintained a positive stance on Arcturus Therapeutics (NASDAQ:ARCT) shares, reiterating a Buy rating and a price target of $63. Currently trading at $16.97, the stock has significant ...

Meiji Seika Pharma Co. said on Dec. 25 it is seeking 10 million yen ($63,500) in damages from Kazuhiro Haraguchi, a Lower House member of the main opposition Constitutional Democratic Party of Japan.

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announced that the company has concluded an investment agreement ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 Meiji Seika Pharma Co., Ltd. (Headquarters ...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announced that the company has ...

TOKYO, January 10, 2025--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter ...